{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:16:15Z","timestamp":1781709375197,"version":"3.54.5"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Recent studies have shown the efficacy for using spironolactone to treat heart failure with reduced ejection fraction (HFrEF), but the efficacy of spironolactone for heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) is unclear. This meta-analysis investigated the efficacy and safety of spironolactone in patients with HFmrEF and HFpEF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and results:<\/jats:title>\n            <jats:p>We searched several databases including PubMed and the Cochrane Collaboration, for randomized controlled trials (RCTs) that assessed spironolactone treatment in HFmrEF and HFpEF. Eleven RCTs including 4539 patients were included. Spironolactone reduced hospitalizations (odds ratio [OR], 0.84; 95% confidence interval [CI], 0.73\u20130.95; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.006), improved New York Heart Association functional classifications (NYHA-FC) (OR, 0.35; 95% CI, 0.19\u20130.66; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001), decreased the levels of brain natriuretic peptide (BNP) (mean difference [MD],\u200a\u2212\u200a44.80\u200apg\/mL; 95% CI, \u221273.44\u2013\u221216.17; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.002), procollagen type I C-terminal propeptide (PICP) (MD, \u221227.04\u200ang\/mL; 95% CI, \u221240.77\u2013\u221213.32, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001) in HFmrEF and HFpEF. Besides, it improved 6-minute walking distances (6-MWD) (standard weighted mean difference [SMD], 0.45 m; 95% CI, 0.27\u20130.64; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001), decreased amino-terminal peptide of procollagen type-III (PIIINP) (SMD, \u22120.37\u200a\u03bcg\/L; 95% CI, \u22120.59\u2013\u22120.15; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001) in HFpEF only. The risks of hyperkalemia (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001) and gynecomastia (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001) were increased.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Patients with HFmrEF and HFpEF could benefit from spironolactone treatment, with reduced hospitalizations, BNP levels, improved NYHA-FC, alleviated myocardial fibrosis by decreasing serum PICP in HFmrEF and HFpEF, decreased PIIINP levels and increased 6-MWD only in HFpEF. The risks of hyperkalemia and gynecomastia were significantly increased with the spironolactone treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014967","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T18:57:14Z","timestamp":1553799434000},"page":"e14967","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction"],"prefix":"10.1097","volume":"98","author":[{"given":"Yajie","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuolin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Yishu","family":"Wang","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine at Dartmouth, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","article-title":"Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences","volume":"27","author":"Yang","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 esc guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/ACO.0000000000000276","article-title":"Diastolic heart failure: diagnosis and therapy","volume":"29","author":"Nicoara","year":"2016","journal-title":"Curr Opin Anaesthesiol"},{"key":"R4-20230914","first-page":"407","article-title":"Heart failure","volume":"68","author":"Gedela","year":"2015","journal-title":"S D Med"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 esc guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the esc","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Failure"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"Accf aha guideline for the management of heart failure executive summary a report of the American college of cardiology foundation American heart association task force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4070\/kcj.2017.0009","article-title":"Korean guidelines for diagnosis and management of chronic heart failure","volume":"47","author":"Kim","year":"2017","journal-title":"Korean Circ J"},{"key":"R10-20230914","first-page":"98","article-title":"2014 Chinese guidelines for diagnosis and management of chronic heart failure","volume":"42","author":"Jun Huang","year":"2014","journal-title":"Chin J Cardiol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.109.895235","article-title":"Aldosterone receptor antagonists: effective but often forgotten","volume":"121","author":"Maron","year":"2010","journal-title":"Circulation"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ehjcvp\/pvw016","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives","volume":"3","author":"Pitt","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactoneclinical perspective","volume":"132","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"e002137","DOI":"10.1161\/JAHA.115.002137","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: A meta-analysis and systematic review","volume":"4","author":"Pandey","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCHEARTFAILURE.112.000074","article-title":"Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"Li","year":"2013","journal-title":"Circ Heart fail"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-014-0261-8","article-title":"Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials","volume":"13","author":"Chen","year":"2015","journal-title":"BMC Med"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/14740338.2016.1163335","article-title":"The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure","volume":"15","author":"Pitt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R20-20230914","first-page":"897","article-title":"Heart failure with preserved ejection fraction","volume":"376","author":"Redfield","year":"2017","journal-title":"N Engl J Med"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1161\/CIR.0000000000000523","article-title":"Methodological standards for meta-analyses and qualitative systematic reviews of cardiac prevention and treatment studies: a scientific statement from the American heart association","volume":"136","author":"Rao","year":"2017","journal-title":"Circulation"},{"key":"R23-20230914","article-title":"Cochrane handbook","author":"Sally Green","year":"2008","journal-title":"2008 The Cochrane Collaboration"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A randomized study of the beneficial effects of aldosterone antagonism on lv function, structure, and fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc Imag"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12471-016-0817-7","article-title":"Biomarkers in heart failure with preserved ejection fraction","volume":"24","author":"Meijers","year":"2016","journal-title":"Neth Heart J"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MCA.0b013e32833fd243","article-title":"The effects of spironolactone on atrial remodeling in patients with preserved left ventricular function after an acute myocardial infarction: a randomized follow-up study","volume":"21","author":"Kayrak","year":"2010","journal-title":"Coron Artery Dis"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/heartjnl-2012-303329","article-title":"Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade","volume":"99","author":"Kosmala","year":"2013","journal-title":"Heart"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","article-title":"Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction","volume":"20","author":"Kurrelmeyer","year":"2014","journal-title":"J Card Fail"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/clc.4960281008","article-title":"Spironolactone improves diastolic function in the elderly","volume":"28","author":"Roongsritong","year":"2005","journal-title":"Clin Cardiol"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/1755-5922.12006","article-title":"Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction?","volume":"31","author":"Vatankulu","year":"2013","journal-title":"Cardiovasc Ther"},{"key":"R32-20230914","first-page":"567","article-title":"Effects of spironolactone in treatment of elderly hypertension patients with diastolic heart failure","volume":"25","author":"Liu","year":"2006","journal-title":"Chin J New Drugs Clin Rem"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/CIRCHEARTFAILURE.115.002249","article-title":"Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"8","author":"Amil","year":"2015","journal-title":"Circ Heart Fail"},{"key":"R35-20230914","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Lewis. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Scott","year":"2016","journal-title":"Eur Heart J"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","article-title":"Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction","volume":"68","author":"Kosmala","year":"2016","journal-title":"J Am College Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201903290-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T20:24:09Z","timestamp":1694723049000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201903290-00026"}},"subtitle":["A meta-analysis of randomized clinical trials"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014967","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}